HVEM (herpesvirus entry mediator), also referred to as CD270, TR2 and ATAR, is a single-pass, type I transmembrane glycoprotein in the TNF receptor superfamily (TNFRSF14).  HVEM is widely expressed, with the highest expression in lung, spleen and thymus. It is found in peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells. The extracellular domain (ECD) of HVEM contains three cysteine­rich repeats characteristic of TNF receptor superfamily members. The ECD of HVEM interacts directly with the herpes simplex virus (HSV) envelope glycoprotein D, contributing partly to HSV entry mechanism. The short cytoplasmic region of HVEM lacks a death domain, but contains a TRAF interaction motif for recruiting TRAFs and transducing signaling pathways that activate inflammatory and inhibitory T-cell immune responses. Two TNF superfamily ligands lymphotoxin-α (also known as TNF-β) and LIGHT (TNFSF14) are identified as cellular ligands for HVEM. Both ligands initiate the positive signaling activities. However, recent studies have also revealed that HVEM may be involved in the inhibitory pathway for T cells through serving as a receptor for BTLA (B and T lymphocyte attenuator) or CD272.

HVEM (herpesvirus entry mediator), also referred to as CD270, TR2 and ATAR, is a single-pass, type I transmembrane glycoprotein in the TNF receptor superfamily (TNFRSF14).  HVEM is widely expressed, with the highest expression in lung, spleen and thymus. It is found in peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells. The extracellular domain (ECD) of HVEM contains three cysteine­rich repeats characteristic of TNF receptor superfamily members. The ECD of HVEM interacts directly with the herpes simplex virus (HSV) envelope glycoprotein D, contributing partly to HSV entry mechanism. The short cytoplasmic region of HVEM lacks a death domain, but contains a TRAF interaction motif for recruiting TRAFs and transducing signaling pathways that activate inflammatory and inhibitory T-cell immune responses. Two TNF superfamily ligands lymphotoxin-α (also known as TNF-β) and LIGHT (TNFSF14) are identified as cellular ligands for HVEM. Both ligands initiate the positive signaling activities. However, recent studies have also revealed that HVEM may be involved in the inhibitory pathway for T cells through serving as a receptor for BTLA (B and T lymphocyte attenuator) or CD272.

  

Product Details

 

Gene Symbol: TNFRSF14; CD270; TR2; ATAR; HVEA; LIGHTR; UNQ329/PRO509

  

NCBI Gene ID: 8764

 

Uniprot Entry: Q92956

 

Construct Details: The recombinant human HVEM-Fc fusion is expressed as a 388 amino acid protein consisting of Leu39 - Ser199 region of HVEM (UniProt accession #Q92956) and a C-terminal Fc from human IgG1, which exists as a dimer under non-reducing conditions (see the gel image inserted above).  

   

Source: Human cells stably expressing human HVEM-Fc and growing in chemical-defined media with no animal components or antibiotics

 

Deduced Amino Acid Sequence: 

        10         20         30         40         50         60 

LPSCKEDEYP VGSECCPKCS PGYRVKEACG ELTGTVCEPC PPGTYIAHLN GLSKCLQCQM 

        70         80         90        100        110        120 

CDPAMGLRAS RNCSRTENAV CGCSPGHFCI VQDGDHCAAC RAYATSSPGQ RVQKGGTESQ 

       130        140        150        160        170        180 

DTLCQNCPPG TFSPNGTLEE CQHQTKCSWL VTKAGAGTSS STGTHTCPPC PAPELLGGPS 

       190        200        210        220        230        240 

VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 

       250        260        270        280        290        300 

YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT 

       310        320        330        340        350        360 

KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ 

       370        380 

GNVFSCSVMH EALHNHYTQK SLSLSPGK 

 

M.W.: Calculated molecular mass (kDa): 42.4; Estimated by SDS-PAGE under reducing condition (kDa): 55-60

 

Calculated PI: 6.62

 

Calculated extinction coefficients (M-1 cm-1, at 280nm): 48495

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as "DTT: +")

 

Formulation: Supplied at 0.5 mg/ml in sterile PBS pH7.4 (carrier & preservative free).

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Binds to its ligands, BTLA/CD272 (SKU#FCL0722), TNF­β and LIGHT, and inhibits TNF­β- and LIGHT­mediated signaling acitivities including cytotoxicity in L-929 mouse fibroblast cells.

 

 

  

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks.

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

 

1. Cell 87:427 (1996).

2. J. Biol. Chem. 272:13471 (1997). 

3. Immunity 8:21 (1998).

4. Immunol. Rev.202: 49 (2004). 

5. Proc. Natl. Acad. Sci. 102: 13218 (2005). 

 

 

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: FCL0096-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.